Posted to Announcement on 9/22/2010 at 11:50 AM
CSL Behring announces publication of the latest in its ongoing Key Issues Dialogue Series – "Hereditary Angioedema (HAE) in the US." The Dialogue brought together thought leaders from the medical science and patient advocacy communities to examine critical issues affecting people with HAE.
The participants included prominent physician-researchers who agreed that a lack of understanding about HAE is commonplace in the medical community, often resulting in unnecessary surgery and inappropriate treatment. The complete Dialogue is available for download: http://www.cslbehring-us.com/about-CSL-Behring/dialogue-series.htm
CSL Behring is a leader in the plasma protein therapeutics industry. The company manufactures and markets a range of plasma-derived and recombinant therapies worldwide for the treatment of rare and serious diseases and for use in cardiac surgery, organ transplantation and burn treatment, and to prevent hemolytic diseases in the newborn.
Related Link: Click to View
Share This Post With Others